FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138489682> ?p ?o ?g. }

• W2138489682 endingPage "34" @default.
• W2138489682 startingPage "29" @default.
• W2138489682 abstract "To evaluate the clinical utility of capromab pendetide imaging with single photon emission computed tomography coregistration with computed tomography (SPECT/CT) in primary prostate cancer (CaP) for pretreatment prognostic staging and localization of biologic target volumes (BTV) for individualized image-guided radiotherapy dose escalation (IGRT-DE).Patients consecutively presenting for primary radiotherapy (February 1997 to December 2002), having a clinical diagnosis of localized CaP, were evaluated for tumor stage using conventional staging and SPECT/CT (N=239). Distant metastatic uptake (mets) were identified by SPECT/CT in 22 (9.2%). None of the suspected mets could be clinically confirmed. Thus, all subjects were followed without alteration in disease management. The SPECT/CT pelvic images defined BTV for IGRT-DE (+150% brachytherapy dose) without (n=150) or with (n=89) external radiation of 45 Gy. The National Comprehensive Cancer Network criteria defined risk groups (RG). The median survivor follow-up was 7 years. Biochemical disease-free survival (bDFS) was reported by clinical nadir +2 ng/mL (CN+2) criteria. Statistical analyses included Kaplan-Meier, multivariate analysis, and Concordance-index models.At 10-year analyses, overall survival was 84.8% and bDFS was 84.6%. With stratification by RG, CN+2 bDFS was 93.5% for the low-RG (n=116), 78.7% for the intermediate-RG (n=94), and 68.8% for the high-RG (n=29), p=0.0002. With stratification by pretreatment SPECT/CT findings, bDFS was 65.5% in patients with suspected mets (n=22) vs. 86.6% in patients with only localized uptake (n=217), p=0.0014. CaP disease-specific survival (DSS) was 97.7% for the cohort. With stratification by SPECT/CT findings, DSS was 86.4% (with suspected mets) vs. 99.0% (localized only), p=0.0001. Using multivariate analysis, the DSS hazard ratio for SPECT/CT findings (mets vs. localized) was 3.58 (p=0.0026). Concordance-index tests, based on all data, by CN+2 bDFS criteria were 0.710 for RG alone and 0.773 for SPECT/CT + RG.Through long-term outcomes we demonstrate statistically significant bDFS and DSS predictive value for pretreatment capromab pendetide SPECT/CT imaging in primary CaP. Dual clinical utility is demonstrated, using SPECT/CT to define BTV for individualized IGRT-DE." @default.
• W2138489682 created "2016-06-24" @default.
• W2138489682 creator A5034662620 @default.
• W2138489682 creator A5048396870 @default.
• W2138489682 creator A5051558732 @default.
• W2138489682 creator A5053895081 @default.
• W2138489682 creator A5059061070 @default.
• W2138489682 creator A5078301936 @default.
• W2138489682 creator A5090000520 @default.
• W2138489682 creator A5090754156 @default.
• W2138489682 date "2011-09-01" @default.
• W2138489682 modified "2023-09-26" @default.
• W2138489682 title "Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer" @default.
• W2138489682 cites W1971646649 @default.
• W2138489682 cites W1981695099 @default.
• W2138489682 cites W1982998352 @default.
• W2138489682 cites W1995588150 @default.
• W2138489682 cites W2005059357 @default.
• W2138489682 cites W2007747396 @default.
• W2138489682 cites W2014924758 @default.
• W2138489682 cites W2024673309 @default.
• W2138489682 cites W2040259127 @default.
• W2138489682 cites W2052741059 @default.
• W2138489682 cites W2067482928 @default.
• W2138489682 cites W2077793947 @default.
• W2138489682 cites W2083115317 @default.
• W2138489682 cites W2092393050 @default.
• W2138489682 cites W2093867637 @default.
• W2138489682 cites W2101995865 @default.
• W2138489682 cites W2123377260 @default.
• W2138489682 cites W2147424850 @default.
• W2138489682 cites W2163470211 @default.
• W2138489682 cites W2321734649 @default.
• W2138489682 cites W3023687301 @default.
• W2138489682 doi "https://doi.org/10.1016/j.ijrobp.2010.05.053" @default.
• W2138489682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20961696" @default.
• W2138489682 hasPublicationYear "2011" @default.
• W2138489682 type Work @default.
• W2138489682 sameAs 2138489682 @default.
• W2138489682 citedByCount "30" @default.
• W2138489682 countsByYear W21384896822012 @default.
• W2138489682 countsByYear W21384896822013 @default.
• W2138489682 countsByYear W21384896822014 @default.
• W2138489682 countsByYear W21384896822015 @default.
• W2138489682 countsByYear W21384896822016 @default.
• W2138489682 countsByYear W21384896822017 @default.
• W2138489682 countsByYear W21384896822018 @default.
• W2138489682 countsByYear W21384896822019 @default.
• W2138489682 countsByYear W21384896822020 @default.
• W2138489682 countsByYear W21384896822022 @default.
• W2138489682 countsByYear W21384896822023 @default.
• W2138489682 crossrefType "journal-article" @default.
• W2138489682 hasAuthorship W2138489682A5034662620 @default.
• W2138489682 hasAuthorship W2138489682A5048396870 @default.
• W2138489682 hasAuthorship W2138489682A5051558732 @default.
• W2138489682 hasAuthorship W2138489682A5053895081 @default.
• W2138489682 hasAuthorship W2138489682A5059061070 @default.
• W2138489682 hasAuthorship W2138489682A5078301936 @default.
• W2138489682 hasAuthorship W2138489682A5090000520 @default.
• W2138489682 hasAuthorship W2138489682A5090754156 @default.
• W2138489682 hasConcept C121608353 @default.
• W2138489682 hasConcept C126322002 @default.
• W2138489682 hasConcept C126838900 @default.
• W2138489682 hasConcept C146357865 @default.
• W2138489682 hasConcept C151730666 @default.
• W2138489682 hasConcept C160798450 @default.
• W2138489682 hasConcept C2777416452 @default.
• W2138489682 hasConcept C2780192828 @default.
• W2138489682 hasConcept C2780441642 @default.
• W2138489682 hasConcept C2989005 @default.
• W2138489682 hasConcept C509974204 @default.
• W2138489682 hasConcept C71924100 @default.
• W2138489682 hasConcept C72563966 @default.
• W2138489682 hasConcept C86803240 @default.
• W2138489682 hasConcept C9267231 @default.
• W2138489682 hasConceptScore W2138489682C121608353 @default.
• W2138489682 hasConceptScore W2138489682C126322002 @default.
• W2138489682 hasConceptScore W2138489682C126838900 @default.
• W2138489682 hasConceptScore W2138489682C146357865 @default.
• W2138489682 hasConceptScore W2138489682C151730666 @default.
• W2138489682 hasConceptScore W2138489682C160798450 @default.
• W2138489682 hasConceptScore W2138489682C2777416452 @default.
• W2138489682 hasConceptScore W2138489682C2780192828 @default.
• W2138489682 hasConceptScore W2138489682C2780441642 @default.
• W2138489682 hasConceptScore W2138489682C2989005 @default.
• W2138489682 hasConceptScore W2138489682C509974204 @default.
• W2138489682 hasConceptScore W2138489682C71924100 @default.
• W2138489682 hasConceptScore W2138489682C72563966 @default.
• W2138489682 hasConceptScore W2138489682C86803240 @default.
• W2138489682 hasConceptScore W2138489682C9267231 @default.
• W2138489682 hasIssue "1" @default.
• W2138489682 hasLocation W21384896821 @default.
• W2138489682 hasLocation W21384896822 @default.
• W2138489682 hasOpenAccess W2138489682 @default.
• W2138489682 hasPrimaryLocation W21384896821 @default.
• W2138489682 hasRelatedWork W1982503259 @default.
• W2138489682 hasRelatedWork W2010917826 @default.
• W2138489682 hasRelatedWork W2394137042 @default.

• next